Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Bioardis LLC has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. Interestingly, these actions are both located within 1 distinct art unit, suggesting a very tight technical focus for the company's current filings. Despite being in the same art unit, the cases are handled by 2 distinct examiners, which provides the applicant with two different perspectives from within the same specialized department of the patent office.
HADDAD, MAHER M is the busiest examiner for the company, with 1 pending office action. Since there are 2 pending office actions and 2 distinct examiners, the workload is evenly divided, with the busiest examiner managing a portion of the cases. The concentration in 1 distinct art unit combined with the use of multiple examiners means the applicant is dealing with different individuals who likely share a similar technical background. This environment allows for some consistency in technical standards while still requiring individualized examiner strategies.
For a practitioner, the Biotechnology & Pharmaceuticals focus within a single art unit simplifies the technical landscape. However, the 1 pending office action under the busiest examiner must be handled with an awareness of the other examiner's approach. The outcome of these 2 pending office actions will significantly impact the company's patent position in this specific field. Coordinating the responses to the two different examiners while maintaining a consistent technical narrative within the art unit is a key strategic priority for Bioardis LLC.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DAHLE, CHUN WU | 1 | 50.2% | +51.1% |
| HADDAD, MAHER M | 1 | 50.6% | +53.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18268215 | MESOTHELIN BINDING MOLECULES AND USES THEREOF | DAHLE, CHUN WU | — |
| 18258203 | FAP BINDING MOLECULES AND USES THEREOF | HADDAD, MAHER M | — |
| Art Unit | Apps |
|---|---|
| 1641 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18268215 | MESOTHELIN BINDING MOLECULES AND USES THEREOF | DAHLE, CHUN WU | 1641 | §112 | Non-Final OA | — | Pending | Jun 16, 2023 |
| 18258203 | FAP BINDING MOLECULES AND USES THEREOF | HADDAD, MAHER M | 1641 | §112 | Non-Final OA | — | Pending | Jun 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBioardis LLC has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Chun Wu Dahle has the most, with 1 of Bioardis LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
